OBJECTIVE: Hypertriglyceridemia is a risk factor for coronary heart disease. The aim of this study was to determine the effect of amino acid (AA) supplementation on plasma, liver, and muscle lipid concentrations and insulin sensitivity in the elderly. METHODS: Twelve impaired glucose tolerant elderly (mean +/- SD 67.0 +/- 5.6 y of age, seven women and five men) ingested 11 g of essential AAs plus arginine twice a day for 16 wk, after a 7-wk control run-in. Diet and activity were not otherwise modified. Plasma lipid concentrations and oral glucose tolerance were measured every fourth week and tissue lipid concentrations (magnetic resonance spectroscopy) every eighth week. RESULTS: No changes in plasma lipids were observed during the control run-in. AA supplementation lowered plasma triacylglycerol (TG; P < 0.001), total cholesterol (P = 0.048), and very low-density lipoprotein cholesterol (P < 0.001) concentrations. Plasma TG decreased approximately 20% from the initial value of 1.45 +/- 0.18 mmol/L (mean +/- SE, 128 +/- 16 mg/dL), with the greatest decrease in the subjects starting out with the highest concentrations (r = -0.83). Similarly, liver fat content (liver TG/Intralipid standard) decreased approximately 50% from the initial value of 0.34 +/- 0.06 (P = 0.021, n = 8), with the greatest decrease in the subjects who initially had the highest values (r = -0.86). Intramuscular fat content and insulin sensitivity did not change. CONCLUSION: Diet supplementation with AAs lowers plasma TG, total cholesterol, and very low-density lipoprotein cholesterol concentrations and liver lipid content in impaired glucose tolerant elderly. AA supplementation may have a potential role in the treatment of hypertriglyceridemia or hepatic steatosis.
OBJECTIVE:Hypertriglyceridemia is a risk factor for coronary heart disease. The aim of this study was to determine the effect of amino acid (AA) supplementation on plasma, liver, and muscle lipid concentrations and insulin sensitivity in the elderly. METHODS: Twelve impaired glucose tolerant elderly (mean +/- SD 67.0 +/- 5.6 y of age, seven women and five men) ingested 11 g of essential AAs plus arginine twice a day for 16 wk, after a 7-wk control run-in. Diet and activity were not otherwise modified. Plasma lipid concentrations and oral glucose tolerance were measured every fourth week and tissue lipid concentrations (magnetic resonance spectroscopy) every eighth week. RESULTS: No changes in plasma lipids were observed during the control run-in. AA supplementation lowered plasma triacylglycerol (TG; P < 0.001), total cholesterol (P = 0.048), and very low-density lipoprotein cholesterol (P < 0.001) concentrations. Plasma TG decreased approximately 20% from the initial value of 1.45 +/- 0.18 mmol/L (mean +/- SE, 128 +/- 16 mg/dL), with the greatest decrease in the subjects starting out with the highest concentrations (r = -0.83). Similarly, liver fat content (liver TG/Intralipid standard) decreased approximately 50% from the initial value of 0.34 +/- 0.06 (P = 0.021, n = 8), with the greatest decrease in the subjects who initially had the highest values (r = -0.86). Intramuscular fat content and insulin sensitivity did not change. CONCLUSION: Diet supplementation with AAs lowers plasma TG, total cholesterol, and very low-density lipoprotein cholesterol concentrations and liver lipid content in impaired glucose tolerant elderly. AA supplementation may have a potential role in the treatment of hypertriglyceridemia or hepatic steatosis.
Authors: B Morio; J F Hocquette; C Montaurier; Y Boirie; C Bouteloup-Demange; C McCormack; N Fellmann; B Beaufrère; P Ritz Journal: Am J Physiol Endocrinol Metab Date: 2001-01 Impact factor: 4.310
Authors: Melanie G Cree; Bradley R Newcomer; Laura K Read; Melinda Sheffield-Moore; Douglas Paddon-Jones; David Chinkes; Asle Aarsland; Robert R Wolfe Journal: Mech Ageing Dev Date: 2007-08-15 Impact factor: 5.432
Authors: Donald K Layman; Richard A Boileau; Donna J Erickson; James E Painter; Harn Shiue; Carl Sather; Demtra D Christou Journal: J Nutr Date: 2003-02 Impact factor: 4.798
Authors: Robert H Coker; Nicolaas E Deutz; Scott Schutzler; Marjorie Beggs; Sharon Miller; Robert R Wolfe; Jeanne Wei Journal: J Endocrinol Diabetes Obes Date: 2015-04-15
Authors: S Bel-Serrat; T Mouratidou; I Huybrechts; M Cuenca-García; Y Manios; S Gómez-Martínez; D Molnár; A Kafatos; F Gottrand; K Widhalm; M Sjöström; A Wästlund; P Stehle; E Azzini; K Vyncke; M González-Gross; L A Moreno Journal: Eur J Clin Nutr Date: 2014-02-05 Impact factor: 4.016
Authors: G K Raja; M A Sarzynski; P T Katzmarzyk; W D Johnson; Y Tchoukalova; S R Smith; C Bouchard Journal: Int J Obes (Lond) Date: 2013-08-16 Impact factor: 5.095
Authors: Ana Burgeiro; Manuela G Cerqueira; Bárbara M Varela-Rodríguez; Sara Nunes; Paula Neto; Frederico C Pereira; Flávio Reis; Eugénia Carvalho Journal: Nutrients Date: 2017-06-21 Impact factor: 5.717
Authors: Bryce J Marquis; Nicholas M Hurren; Eugenia Carvalho; Il-Young Kim; Scott Schutzler; Gohar Azhar; Robert R Wolfe; Elisabet Børsheim Journal: Curr Dev Nutr Date: 2017-10-17
Authors: Gohar Azhar; Jeanne Y Wei; Scott E Schutzler; Karen Coker; Regina V Gibson; Mitchell F Kirby; Arny A Ferrando; Robert R Wolfe Journal: J Gerontol A Biol Sci Med Sci Date: 2021-06-14 Impact factor: 6.053